Dexcom Welcome Renée Galá to its Board of Directors

DexCom Inc. has added Jazz Pharmaceuticals President/Chief Operating Officer (COO) Renée Galá to its Board of Directors.

Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. In her current role at Jazz Pharmaceuticals Public Limited Company, Galá oversees global business operations including commercial operations, research and development, manufacturing, corporate strategy, and quality. She brings to the Dexcom Board a strong track record of strategic and financial leadership at high-growth companies, including oversight of key international expansion initiatives and business development collaborations.

“We are excited to announce Renée’s appointment to the Dexcom board and benefit from her insights,” Dexcom President/CEO Kevin Sayer said. “Dexcom has a unique opportunity ahead of us to empower greater metabolic health for millions of people around the world. Renée’s extensive experience guiding global finance and global operations including commercial and R&D to drive growth and create shareholder value provides an excellent fit at this key point in Dexcom’s journey.”

Galá has been president/COO of Jazz Pharmaceuticals since 2023; from 2020 to 2023, she served as executive vice president and chief financial officer (CFO) at the company. From January to June 2019, Galá was CFO of GRAIL Inc., a private healthcare company focused on early cancer detection. From December 2014 to January 2019, she was senior vice president and CFO of Theravance Biopharma Inc., a biopharmaceutical company, after its spinof from Theravance Inc. (now INVA). Galá joined Theravance in 2006 and held various roles in the finance organization before leading the company’s spinoff transaction.

Prior to that, Galá served in various roles in global treasury, pharmaceutical sales, and corporate strategy/business development at Eli Lilly and Company (2001-2006). Before joining Eli Lilly, Galá spent seven years in the energy industry in positions focused on corporate finance, project finance, and mergers and acquisitions.

Galá has served as a non-executive director for multiple companies in the biotech/life sciences industry, including Gossamer Bio, Gyroscope Therapeutics (acquired by Novartis), and Corcept Therapeutics. She earned a bachelor of science degree in mathematics from Vanderbilt University and an MBA from Columbia Business School.

Dexcom empowers people to take control of health through biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed the ways in which people manage diabetes and track their glucose.